Kyowa Kirin Co., Ltd. and Kura Oncology, Inc. have initiated a Phase 2 registrational clinical trial (jRCT2031250550) for ziftomenib, an oral menin inhibitor, targeting relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). This trial, which has begun dosing its first patient in Japan, aims to address a significant unmet need, as NPM1 mutations are present in approximately 30% of AML patients. Following the trial’s completion, Kyowa Kirin plans to seek regulatory approval in Japan, building on ziftomenib’s recent FDA approval in the U.S. under the brand name KOMZIFTI™.

The significance of this trial lies in the urgent need for new therapeutic options for patients with R/R NPM1-m AML, who often face limited treatment alternatives. Ziftomenib has demonstrated a favorable efficacy and safety profile in previous clinical evaluations, with the trial’s primary endpoint focusing on a composite complete remission rate that includes both complete remission (CR) and complete remission with partial hematologic recovery (CRh). The collaboration between Kyowa Kirin and Kura Oncology emphasizes a patient-centered approach in drug development, particularly in hematologic malignancies, and aims to provide new hope for patients who currently lack satisfactory treatment options.

The advancement of ziftomenib into this Phase 2 trial marks a pivotal shift in the research landscape for AML therapies. It highlights the potential for oral menin inhibitors not only to improve outcomes for patients with specific genetic profiles but also to influence broader drug development timelines for similar targeted therapies. As ziftomenib progresses, it may catalyze further exploration into menin inhibition and its role in combination therapies, ultimately expanding treatment strategies for hematologic malignancies.

Source: globenewswire.com